Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site.

The crystal structures of the wild-type HIV-1 protease (PR) and the two resistant variants, PR(V82A) and PR(L90M), have been determined in complex with the antiviral drug, indinavir, to gain insight into the molecular basis of drug resistance. V82A and L90M correspond to an active site mutation and nonactive site mutation, respectively. The inhibition (K(i)) of PR(V82A) and PR(L90M) was 3.3- and 0.16-fold, respectively, relative to the value for PR. They showed only a modest decrease, of 10-15%, in their k(cat)/K(m) values relative to PR. The crystal structures were refined to resolutions of 1.25-1.4 A to reveal critical features associated with inhibitor resistance. PR(V82A) showed local changes in residues 81-82 at the site of the mutation, while PR(L90M) showed local changes near Met90 and an additional interaction with indinavir. These structural differences concur with the kinetic data.

[1]  J. Ermolieff,et al.  Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo. , 1997, Biochemistry.

[2]  L. Bacheler,et al.  Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency. , 1998, Biochemistry.

[3]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[4]  S. Gulnik,et al.  Drug resistance mutations can affect dimer stability of HIV‐1 protease at neutral pH , 1999, Protein science : a publication of the Protein Society.

[5]  Amilcar Tanuri,et al.  Analysis of the protease sequences of HIV-1 infected individuals after Indinavir monotherapy. , 2003, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[6]  C. Schiffer,et al.  Viability of a Drug-Resistant Human Immunodeficiency Virus Type 1 Protease Variant: Structural Insights for Better Antiviral Therapy , 2003, Journal of Virology.

[7]  P. Kraulis.  A program to produce both detailed and schematic plots of protein structures , 1991 .

[8]  H. B. Schock,et al.  Three-dimensional Structure of a Mutant HIV-1 Protease Displaying Cross-resistance to All Protease Inhibitors in Clinical Trials (*) , 1995, The Journal of Biological Chemistry.

[9]  Irene T Weber,et al.  Combining mutations in HIV‐1 protease to understand mechanisms of resistance , 2002, Proteins.

[10]  J. Hermans,et al.  A different best rigid-body molecular fit routine , 1977 .

[11]  Thomas D. Wu,et al.  Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments , 2003, Journal of Virology.

[12]  L. Kuo,et al.  Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases. , 1996, The Journal of biological chemistry.

[13]  J. Louis,et al.  Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. , 2000, European journal of biochemistry.

[14]  Irene T Weber,et al.  Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. , 2002, European journal of biochemistry.

[15]  J. Mellors,et al.  Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor , 1996, Journal of virology.

[16]  B. Korber,et al.  Associations between amino acids in the evolution of HIV type 1 protease sequences under indinavir therapy. , 1999, AIDS research and human retroviruses.

[17]  Celia A Schiffer,et al.  Lack of synergy for inhibitors targeting a multi‐drug‐resistant HIV‐1 protease , 2002, Protein science : a publication of the Protein Society.

[18]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[19]  A. Gronenborn,et al.  HIV-I protease: Maturation, enzyme specificity, and drug resistance , 2000 .

[20]  G. Sheldrick,et al.  SHELXL: high-resolution refinement. , 1997, Methods in enzymology.

[21]  G. Marius Clore,et al.  Autoprocessing of HIV-1 protease is tightly coupled to protein folding , 1999, Nature Structural Biology.

[22]  Brendan A. Larder,et al.  Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples , 2000, AIDS.

[23]  S. Gulnik,et al.  Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. , 1995, Biochemistry.

[24]  F. Mammano,et al.  Loss of Viral Fitness Associated with Multiple Gag and Gag-Pol Processing Defects in Human Immunodeficiency Virus Type 1 Variants Selected for Resistance to Protease Inhibitors In Vivo , 1998, Journal of Virology.

[25]  T. Schroer,et al.  Subunit organization in cytoplasmic dynein subcomplexes , 2002, Protein science : a publication of the Protein Society.

[26]  L Hong,et al.  Crystal structure of an in vivo HIV‐1 protease mutant in complex with saquinavir: Insights into the mechanisms of drug resistance , 2000, Protein science : a publication of the Protein Society.

[27]  A Wlodawer,et al.  Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate. , 1998, Biochemistry.

[28]  H. B. Schock,et al.  An alternate binding site for the P1-P3 group of a class of potent HIV-1 protease inhibitors as a result of concerted structural change in the 80s loop of the protease. , 2000, Acta crystallographica. Section D, Biological crystallography.

[29]  J. Navaza,et al.  AMoRe: an automated package for molecular replacement , 1994 .

[30]  J. Louis,et al.  Structural implications of drug‐resistant mutants of HIV‐1 protease: High‐resolution crystal structures of the mutant protease/substrate analogue complexes , 2001, Proteins.

[31]  E A Merritt,et al.  Expanding the model: anisotropic displacement parameters in protein structure refinement. , 1999, Acta crystallographica. Section D, Biological crystallography.